Certara assumed with an Equal Weight at Morgan Stanley

Morgan Stanley assumed coverage of Certara (CERT) with an Equal Weight rating and $16 price target The firm says it awaits further potential updates on Certara’s strategic review of the regulatory services business and management commentary regarding the near- or mid-term impact that may result from Certara’s opportunity set coming from the FDA’s previous announcement to gradually reduce animal testing in favor of new approach methodologies.